Phase 3Status unknown
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Active-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
- Sponsor
- Hanlim Pharm. Co., Ltd. (Industry)
- Enrolment
- 156 planned
- Conditions
- Primary Hypercholesterolemia; Hypertension
- Interventions
- Experimental : Ezetimibe / Rosuvastatin + Telmisartan; Active comparator1 : Ezetimibe / Rosuvastatin; Active comparator2 : Telmisartan
- Ages
- adults, older adults
- Registry
- NCT04659070
Full record on ClinicalTrials.gov
From the registry
This study is a multicenter, Randomized, double-blind, acitve-controlled, Phase 3 Clinical Trial in 8 weeks for screening, twice Investigational product administer, Follow up visit.
Primary outcomes
- Mean sitting systolic blood pressure (MSSBP)
- Low density lipoprotein cholesterol (LDL-C)
History
Primary completion
Registered
Started